DK2714004T3 - Peptidformuleringer med kontrolleret frigivelse - Google Patents

Peptidformuleringer med kontrolleret frigivelse Download PDF

Info

Publication number
DK2714004T3
DK2714004T3 DK12731315.3T DK12731315T DK2714004T3 DK 2714004 T3 DK2714004 T3 DK 2714004T3 DK 12731315 T DK12731315 T DK 12731315T DK 2714004 T3 DK2714004 T3 DK 2714004T3
Authority
DK
Denmark
Prior art keywords
controlled release
peptide formulations
release peptide
formulations
controlled
Prior art date
Application number
DK12731315.3T
Other languages
Danish (da)
English (en)
Inventor
Fredrik Tiberg
Catalin Nistor
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2714004(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Application granted granted Critical
Publication of DK2714004T3 publication Critical patent/DK2714004T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
DK12731315.3T 2011-05-25 2012-05-25 Peptidformuleringer med kontrolleret frigivelse DK2714004T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161489886P 2011-05-25 2011-05-25
PCT/EP2012/059917 WO2012160213A1 (en) 2011-05-25 2012-05-25 Controlled release peptide formulations

Publications (1)

Publication Number Publication Date
DK2714004T3 true DK2714004T3 (da) 2024-06-10

Family

ID=46456496

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12731315.3T DK2714004T3 (da) 2011-05-25 2012-05-25 Peptidformuleringer med kontrolleret frigivelse

Country Status (37)

Country Link
US (3) US11433120B2 (enExample)
EP (2) EP4427814A3 (enExample)
JP (2) JP6265888B2 (enExample)
KR (1) KR102066755B1 (enExample)
CN (2) CN103702662B (enExample)
AR (1) AR086577A1 (enExample)
AU (2) AU2012260821B2 (enExample)
BR (1) BR112013030104A8 (enExample)
CA (1) CA2836847C (enExample)
CL (1) CL2013003365A1 (enExample)
CO (1) CO6900117A2 (enExample)
CR (1) CR20130653A (enExample)
CU (1) CU20130158A7 (enExample)
DK (1) DK2714004T3 (enExample)
DO (1) DOP2013000275A (enExample)
EA (1) EA036213B1 (enExample)
EC (1) ECSP13013107A (enExample)
ES (1) ES2984717T3 (enExample)
FI (1) FI2714004T3 (enExample)
GT (1) GT201300292A (enExample)
HR (1) HRP20240781T1 (enExample)
HU (1) HUE067389T2 (enExample)
IL (1) IL229376B (enExample)
LT (1) LT2714004T (enExample)
MX (1) MX361716B (enExample)
MY (1) MY177820A (enExample)
NI (1) NI201300127A (enExample)
PE (1) PE20141484A1 (enExample)
PH (1) PH12013502550A1 (enExample)
PL (1) PL2714004T3 (enExample)
PT (1) PT2714004T (enExample)
RS (1) RS65702B1 (enExample)
SG (1) SG194865A1 (enExample)
SI (1) SI2714004T1 (enExample)
TW (1) TWI624271B (enExample)
WO (1) WO2012160213A1 (enExample)
ZA (1) ZA201309653B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1768650T3 (pl) * 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
JP6375289B2 (ja) * 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
PE20150195A1 (es) * 2012-05-25 2015-02-27 Camarus Ab Formulaciones de agonistas del receptor de somatostatina
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
ES2837803T3 (es) 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
JP7527785B2 (ja) 2016-09-15 2024-08-05 カムルス エービー プロスタサイクリン類似体製剤
MX383392B (es) 2016-09-27 2025-03-13 Camurus Ab Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
WO2019099735A1 (en) * 2017-11-15 2019-05-23 Rhythm Pharmaceuticals, Inc. Sustained release peptide formulations
US12247052B2 (en) 2018-03-02 2025-03-11 Elicio Therapeutics, Inc. CpG amphiphiles and uses thereof
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
JP2022525781A (ja) 2019-03-20 2022-05-19 マサチューセッツ インスティテュート オブ テクノロジー 免疫細胞療法における両親媒性物質の使用およびそのための組成物
CA3141337A1 (en) * 2019-05-24 2020-12-03 Piedmont Animal Health Inc. Long-acting injectable formulations and use thereof
MX2021014450A (es) 2019-05-29 2022-01-06 Camurus Ab Composiciones de liberacion controlada de lipidos.
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
CA3217408A1 (en) * 2021-05-04 2022-11-10 Fredrik Tiberg Compositions and methods for treating neuroendocrine tumors
EP4731247A1 (en) * 2023-06-20 2026-04-29 Camurus AB Compositions and methods for treating acromegaly
WO2025229402A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof
WO2025229403A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof
WO2026125238A1 (en) 2024-12-10 2026-06-18 Camurus Ab Compositions and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1682091T3 (pl) * 2003-11-07 2017-09-29 Camurus Ab Kompozycje lipidów i kationowych peptydów
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
PL1768650T3 (pl) * 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
GB0417388D0 (en) 2004-08-04 2004-09-08 Camurus Ab Composition
JP5513713B2 (ja) 2004-08-04 2014-06-04 カムルス エービー 非層状分散を生じる組成物
KR100983746B1 (ko) * 2005-01-14 2010-09-24 카무러스 에이비 소마토스타틴 유사 제형
EP1843746B1 (en) * 2005-01-14 2011-03-16 Camurus Ab Somatostatin analogue formulations
PL1845942T3 (pl) * 2005-01-14 2014-07-31 Camurus Ab Preparaty analogu GnRH
AU2005325510B2 (en) * 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
EP1909824B1 (en) * 2005-04-08 2011-05-18 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
US8097239B2 (en) * 2005-06-06 2012-01-17 Camurus Ab Controlled-release formulations
PL1888031T3 (pl) * 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US8931272B2 (en) * 2010-10-29 2015-01-13 Ford Global Technologies, Llc Method and system for limiting output of a boosted engine
US9555118B2 (en) * 2011-12-05 2017-01-31 Camrus Ab Robust controlled-release peptide formulations
PE20150195A1 (es) * 2012-05-25 2015-02-27 Camarus Ab Formulaciones de agonistas del receptor de somatostatina
US20230285502A1 (en) * 2016-09-07 2023-09-14 Camurus Ab Mixtures and formulations
MX383392B (es) * 2016-09-27 2025-03-13 Camurus Ab Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).

Also Published As

Publication number Publication date
CA2836847A1 (en) 2012-11-29
AU2012260821B2 (en) 2016-01-07
EP4427814A2 (en) 2024-09-11
NZ617828A (en) 2016-11-25
WO2012160213A1 (en) 2012-11-29
EP2714004A1 (en) 2014-04-09
PH12013502550B1 (en) 2015-08-10
MX361716B (es) 2018-12-14
EP4427814A3 (en) 2024-11-20
AU2016202156A1 (en) 2016-04-28
EA201391675A1 (ru) 2014-08-29
AR086577A1 (es) 2014-01-08
PT2714004T (pt) 2024-07-12
PE20141484A1 (es) 2014-10-31
US20250121035A1 (en) 2025-04-17
GT201300292A (es) 2014-08-05
TW201249463A (en) 2012-12-16
CU20130158A7 (es) 2014-04-24
JP2018076327A (ja) 2018-05-17
CL2013003365A1 (es) 2014-07-25
IL229376A0 (en) 2014-01-30
FI2714004T3 (fi) 2024-07-15
EA036213B1 (ru) 2020-10-14
CR20130653A (es) 2014-03-05
TWI624271B (zh) 2018-05-21
NI201300127A (es) 2014-02-25
SI2714004T1 (sl) 2024-07-31
RS65702B1 (sr) 2024-07-31
CN108283619A (zh) 2018-07-17
HUE067389T2 (hu) 2024-10-28
EP2714004B1 (en) 2024-05-15
BR112013030104A2 (pt) 2016-09-20
CN108283619B (zh) 2021-09-14
CN103702662A (zh) 2014-04-02
AU2016202156B2 (en) 2018-03-22
CA2836847C (en) 2021-06-29
BR112013030104A8 (pt) 2021-09-08
ES2984717T3 (es) 2024-10-30
US20210308226A1 (en) 2021-10-07
MX2013013401A (es) 2013-12-12
ECSP13013107A (es) 2015-03-31
CO6900117A2 (es) 2014-03-20
KR102066755B1 (ko) 2020-01-15
JP6265888B2 (ja) 2018-01-24
PH12013502550A1 (en) 2015-08-10
US11433120B2 (en) 2022-09-06
PL2714004T3 (pl) 2024-08-19
US20140162944A1 (en) 2014-06-12
MY177820A (en) 2020-09-23
DOP2013000275A (es) 2014-05-15
CN103702662B (zh) 2018-07-20
ZA201309653B (en) 2016-05-25
JP6415673B2 (ja) 2018-10-31
SG194865A1 (en) 2013-12-30
KR20140045438A (ko) 2014-04-16
IL229376B (en) 2019-11-28
HRP20240781T1 (hr) 2024-09-13
JP2014520090A (ja) 2014-08-21
LT2714004T (lt) 2024-08-12

Similar Documents

Publication Publication Date Title
DK2787975T3 (da) Robuste formuleringer med kontrolleret frigivelse
CO6900117A2 (es) Formulaciones peptídicas de liberación controlada
DK3091029T5 (da) Anti-IL13-antistofformuleringer
DK2768479T3 (da) Hjælpestoffer til nikotin-indeholdende terapeutiske sammensætninger
DK3170508T3 (da) Vaccineformuleringer
FR2977490B1 (fr) Composition photoprotectrice
EP2753345A4 (en) POLYPEPTIDIMPFSTOFF
DK3072505T3 (da) Testosteronformuleringer
CO6940426A2 (es) Formulaciones farmacéuticas
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
DE112012003251A5 (de) Ausrücksystem
BR112014005756A2 (pt) vacina
DE112012003262A5 (de) Ausrücksystem
EP2742058C0 (en) ANTI-IL-6 VACCINE COMPOSITION
EP2729164A4 (en) FORMULATIONS STABILIZING PROTEINS
CO6960544A2 (es) Preparación de liberación sostenida
CY2022038I1 (el) Λυοφιλοποιημενη παρασκευη κυτταροτοξικων διπεπτιδιων
IL231660A0 (en) Composition
DK2672817T3 (da) Forbedrede insekticide formuleringer
HRP20181667T1 (hr) Pripravak
CO6801767A2 (es) Formulaciones de liberación sostenida de paracetamol
DE112012003257A5 (de) Ausrücksystem
DK2793913T3 (da) Doseringsskema til apolipoproteinformuleringer
DE112012003245A5 (de) Ausrücksystem
GB201105360D0 (en) Formulations